Perspective Therapeutics Reports 50% Response Rate in Neuroendocrine Tumor Trial
Perspective Therapeutics announces 50% objective response rate and 72% progression-free survival in Phase 1/2a clinical trial for SSTR2-positive neuroendocrine tumors.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Perspective Therapeutics, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (23 Oct 2026). Not a valuation or a recommendation.
Down 57.8% over the last month ($2.19 on 19 Oct → $0.92 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $2.19 |
|---|---|
| 20 Oct | $2.30 |
| 21 Oct | $2.30 |
| 22 Oct | $2.26 |
| 23 Oct | $1.61 |
| 26 Oct | $1.21 |
| 27 Oct | $1.19 |
| 28 Oct | $1.25 |
| 29 Oct | $1.17 |
| 30 Oct | $1.15 |
| 2 Nov | $1.04 |
| 3 Nov | $0.88 |
| 4 Nov | $0.87 |
| 5 Nov | $0.79 |
| 6 Nov | $0.84 |
| 9 Nov | $0.86 |
| 10 Nov | $0.79 |
| 11 Nov | $0.83 |
| 12 Nov | $0.84 |
| 13 Nov | $0.94 |
| 16 Nov | $0.92 |
Perspective Therapeutics announces 50% objective response rate and 72% progression-free survival in Phase 1/2a clinical trial for SSTR2-positive neuroendocrine tumors.
Perspective Therapeutics (CATX) receives FDA Fast Track Designation for PSV359 in rare cancer treatment, backed by $236.9M in cash for operations into late 2027.
Track Perspective Therapeutics, Inc. live
Get the next Perspective Therapeutics, Inc. SEC filing seconds after it lands.